(MIRM) – Business Wire
-
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Mirum Pharmaceuticals’ LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada’s CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome
-
Mirum Pharmaceuticals’ LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis
-
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
-
Hepatology Publishes Six-Year Data Demonstrating Improved Clinical Outcomes in Patients with Alagille Syndrome Treated with Mirum’s LIVMARLI
-
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update
-
Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2023 Financial Results and Host Conference Call on February 28, 2024
-
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Mirum Pharmaceuticals Appoints Joanne Quan, MD as Chief Medical Officer
-
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Mirum Pharmaceuticals Announces Preliminary Unaudited 2023 Net Revenue and Provides Corporate Updates
-
Mirum Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
-
Mirum Pharmaceuticals Announces Data from EMBARK Phase 2b Study for Biliary Atresia
-
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Mirum Pharmaceuticals to Present at the 2023 Evercore ISI HealthCONx Conference
-
Mirum Pharmaceuticals Presents New Data at The Liver Meeting®
-
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Mirum Pharmaceuticals to Present at the 2023 UBS Biopharma Conference
-
Mirum Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
-
Mirum Pharmaceuticals to Present New Data at The Liver Meeting®
-
Mirum Pharmaceuticals to Announce Third Quarter 2023 Financial Results and Host Conference Call on November 2, 2023
-
Mirum Pharmaceuticals Announces New PDUFA Date for LIVMARLI for the Treatment of Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis
-
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Mirum Pharmaceuticals Presents LIVMARLI Clinical Data and Real-World Evidence at NASPGHAN
-
Mirum Pharmaceuticals Announces Positive Phase 3 RESTORE Study Results Evaluating Chenodal in Patients with Cerebrotendinous Xanthomatosis
-
Mirum Pharmaceuticals to Highlight LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting
-
Mirum Pharmaceuticals to Present at the 2023 Cantor Global Healthcare Conference
-
Mirum Pharmaceuticals Announces the Appointment of Eric Bjerkholt as Chief Financial Officer
-
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
-
Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere Therapeutics
-
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Mirum Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
-
Mirum Pharmaceuticals to Announce Second Quarter 2023 Financial Results and Host Conference Call on August 3, 2023
-
Mirum’s LIVMARLI® Now Authorized in Canada for Cholestatic Pruritus in Patients with Alagille Syndrome
-
Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Therapeutics
-
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Mirum Pharmaceuticals Showcases Five New LIVMARLI (maralixibat) Presentations at the EASL Congress
-
Event-Free Survival Data from Mirum’s LIVMARLI Alagille Syndrome Program Published in Hepatology
-
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Mirum Pharmaceuticals to Present New LIVMARLI Data at the 2023 EASL Congress
-
Data from Mirum’s LIVMARLI Studies Presented at ESPGHAN Annual Meeting
-
Hepatology Communications Publishes Data from Mirum’s LIVMARLI in Primary Sclerosing Cholangitis
-
Mirum Pharmaceuticals to Showcase LIVMARLI Data at ESPGHAN Annual Meeting
-
Mirum Pharmaceuticals Announces Enrollment Completion in Phase 2b EMBARK Biliary Atresia Study
-
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Mirum Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update
-
Mirum Pharmaceuticals to Announce First Quarter 2023 Financial Results and Host Conference Call on May 4, 2023
Back to MIRM Stock Lookup
